By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in Drugs and Therapies. According to news reporting originating from Arcavacata di Rende, Italy, by NewsRx correspondents, research stated, "The aim of the present study was to enhance cellular uptake of simplified analogs of Linezolid by their incorporation into suitable delivery devices in order to improve the antimicrobial activity of these novel synthesized oxazolidin-2-one derivatives. The oxazolidin-2-one derivatives were synthesized by developing a rather simple one-pot reaction starting from oxiranylmethanol and several primary amines."
Our news editors obtained a quote from the research from the University of Calabria, "Three delivery devices were prepared by following different synthetic approaches, such as single-step free radical grafting, precipitation polymerization and nano-emulsion. Finally, the antimicrobial activity of the novel synthesized compounds, without any vehicle and after their incorporation into the delivery devices, was evaluated against Escherichia coli and Saccharomyces cerevisiae by performing time-kill analyses. The synthesized oxazolidinones exhibited modest antimicrobial activity against E. coli and S. cerevisiae (MIC 16 vg/mL). A good activity was, instead, highlighted after their incorporation into the prepared delivery devices (lecithin-based nano-emulsion, poly(N-vinyl-pyrrolidone)-methacrylic acid grafted copolymer and spherical polymeric nanoparticles) (MIC < 4 vg/mL)."
According to the news editors, the research concluded: "The incorporation into suitable vehicles, indeed, reduced by 4 times the normal MICs of the newly synthesized oxazolilidin-2-ones and represents an effective strategy to overcome cellular penetration constraints. ."
For more information on this research see: Enhanced cellular uptake by "pharmaceutically oriented devices" of new simplified analogs of Linezolid with antimicrobial activity. International Journal of Pharmaceutics, 2014;461(1-2):163-170. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
The news editors report that additional information may be obtained by contacting O.I. Parisi, University of Calabria, Dept. of Comp Engn Modeling Elect & Syst, I-87036 Arcavacata Di Rende, CS, Italy. Additional authors for this research include M. Fiorillo, A. Caruso, A.R. Cappello, C. Saturnino, F. Puoci, A. Panno, V. Dolce, H. El-Kashef and M.S. Sinicropi (see also Drugs and Therapies).
Keywords for this news article include: Italy, Europe, Arcavacata di Rende, Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC